<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">788</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2018-14-3-51-57</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железы</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">ROBOT-ASSISTED PELVIC LYMPH NODE DISSECTION USING ICG TESTING IN PATIENTS WITH PROSTATE CANCER</article-title><trans-title-group xml:lang="ru"><trans-title>РОБОТ-АССИСТИРОВАННАЯ ТАЗОВАЯ ЛИМФАДЕНЭКТОМИЯ С ИСПОЛЬЗОВАНИЕМ ICG-ДИАГНОСТИКИ У ПАЦИЕНТОВ С РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Aboyan</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Абоян</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>70/3 Dolomanovskiy Pereulok, Rostov-on-Don 344011.</p></bio><bio xml:lang="ru"><p>344011 Ростов-на-Дону, пер. Доломановский, 70/3.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pakus</surname><given-names>D. I.</given-names></name><name xml:lang="ru"><surname>Пакус</surname><given-names>Д. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>70/3 Dolomanovskiy Pereulok, Rostov-on-Don 344011.</p></bio><bio xml:lang="ru"><p>344011 Ростов-на-Дону, пер. Доломановский, 70/3.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pakus</surname><given-names>S. M.</given-names></name><name xml:lang="ru"><surname>Пакус</surname><given-names>С. М.</given-names></name></name-alternatives><bio xml:lang="en"><p>70/3 Dolomanovskiy Pereulok, Rostov-on-Don 344011.</p></bio><bio xml:lang="ru"><p>Пакус Сергей Михайлович - врач-уролог. кандидат медицинских наук.  </p><p>344011 Ростов-на-Дону, пер. Доломановский, 70/3.</p></bio><email>sergejj.pakus@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Grachev</surname><given-names>S. V.</given-names></name><name xml:lang="ru"><surname>Грачев</surname><given-names>С. В.</given-names></name></name-alternatives><bio xml:lang="en"><p>70/3 Dolomanovskiy Pereulok, Rostov-on-Don 344011.</p></bio><bio xml:lang="ru"><p>344011 Ростов-на-Дону, пер. Доломановский, 70/3.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Berezin</surname><given-names>K. V.</given-names></name><name xml:lang="ru"><surname>Березин</surname><given-names>К. В.</given-names></name></name-alternatives><bio xml:lang="en"><p>70/3 Dolomanovskiy Pereulok, Rostov-on-Don 344011.</p></bio><bio xml:lang="ru"><p>344011 Ростов-на-Дону, пер. Доломановский, 70/3.</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">“Health” Clinical and Diagnostic Center of Rostov-on-Don</institution></aff><aff><institution xml:lang="ru">МБУЗ «Клинико-диагностический центр «Здоровье» города Ростова-на-Дону»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-09-30" publication-format="electronic"><day>30</day><month>09</month><year>2018</year></pub-date><volume>14</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>51</fpage><lpage>57</lpage><history><date date-type="received" iso-8601-date="2018-02-10"><day>10</day><month>02</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2018-05-03"><day>03</day><month>05</month><year>2018</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/788">https://oncourology.abvpress.ru/oncur/article/view/788</self-uri><abstract xml:lang="en"><p>The objective is to investigate the possibility of using fluorescent testing in robot-assisted radical prostatectomy using indocyanine green (ICG testing) during pelvic lymph node dissection (PLND) in patients with localized prostate cancer.</p><p>Materials and methods. Fifteen minutes prior to robot-assisted PLND, intraprostatic transperineal administration of 0.4 ml of indocyanine green (ICG) per lobe under transrectal ultrasound control was performed. Fluorescence map was used. After activation of the FireFly mode, fluorescence of the lymph nodes was evaluated. If a sentinel lymph node was present, lymph node dissection was performed using the FireFly mode. If fluorescence was diffuse, PLND using this option wasn’t performed.</p><p>Results. In total, 35 patients with localized prostate cancer underwent surgery. Mean age was 62.0 ± 6.5 years (41–68 years), mean prostatespecific antigen level prior to surgery was 15.6 ± 11.3 ng/ml (1.5–27.0 ng/ml).  Postoperative examination revealed micrometastases in the lymph nodes in 7 (20 %) cases. Sentinel lymph nodes were detected in 29 patients. Intraoperative examination revealed sentinel lymph nodes metastases in 6 (17 %) cases, in other cases (83 %) metastases were absent. Morphological examination showed that in 5 (83 %) of 6 patients with lesions in the sentinel lymph node, micrometastases in other lymph nodes were present. In patients without lesions in the sentinel lymph node, no micrometastases in other lymph nodes were observed. PLND complications included lymphocele in 3 (8 %) patients, prolonged drain indwelling time in 5 (14 %) patients.</p><p>Conclusion. Initial experience of our clinic shows reproducibility and low complications profile of fluorescence monitoring in the near-infrared region using ICG testing during robot-assisted PNLD. In conditions of continuous increase in the number of performed robot-assisted radical prostatectomies, ICG testing is a promising minimally invasive method for evaluation of regional metastases allowing to detect the sentinel lymph node. This approach allows to decrease the number of complications associated with PLND.</p></abstract><trans-abstract xml:lang="ru"><p>Цель исследования – изучение возможности применения флуоресцентного исследования при робот-ассистированной радикальной простатэктомии с использованием индоцианина зеленого (ICG-диагностики) во время тазовой лимфаденэктомии (ТЛАЭ) у пациентов с локализованным раком предстательной железы.</p><p>Материалы и методы. Перед выполнением робот-ассистированной ТЛАЭ было проведено интрапростатическое трансперинеальное введение индоцианина зеленого (ICG) под трансректальным ультразвуковым контролем в количестве 0,4 мл в каждую долю за 15 мин до начала оперативного вмешательства. Использовали карту флуоресценции. После активации режима FireFly проводили оценку флуоресценции лимфатических узлов. При наличии «сигнального» лимфатического узла выполняли лимфаденэктомию с использованием режима FireFly. В случае диффузного характера флуоресценции ТЛАЭ с применением данной опции не проводилось.</p><p>Результаты. Были прооперированы 35 пациентов с локализованным раком предстательной железы. Средний возраст составил 62,0± 6,5 года (41–68 лет), средний уровень простатического специфического антигена до операции – 15,6 ± 11,3 нг/мл (1,5–27,0 нг/мл). При послеоперационном исследовании в 7 (20 %) случаях выявлены микрометастазы в лимфатических узлах. «Сигнальные» лимфатические узлы обнаружены у 29 пациентов. При интраоперационном исследовании в 6 (17 %) случаях выявлены метастазы в «сигнальном» лимфатическом узле, в остальных (83 %) случаях метастазы отсутствовали. При морфологическом исследовании у 5 (83 %) из 6 пациентов с поражением «сигнального» лимфатического узла обнаружены микрометастазы в других лимфатических узлах. У пациентов с отсутствием поражения «сигнального» лимфатического узла не выявлено микрометастазов в других лимфатических узлах. Осложнения ТЛАЭ включали лимфоцеле у 3 (8 %) больных, длительное сохранение отделяемого по дренажам у 5 (14 %).</p><p>Заключение. Инициальный опыт нашей клиники показывает воспроизводимость и низкий профиль осложнений флуоресцентного мониторинга в ближней инфракрасной области спектра с использованием ICG-диагностики при выполнении робот-ассистированной ТЛАЭ. В условиях непрерывного увеличения количества выполняемых робот-ассистированных радикальных простатэктомий ICG-диагностика является перспективным минимально-инвазивным методом оценки регионарного метастазирования, позволяющим выявить «сигнальный» лимфатический узел. Данный подход позволяет снизить количество осложнений, связанных с ТЛАЭ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>localized prostate cancer</kwd><kwd>ICG testing</kwd><kwd>robot-assisted pelvic lymph node dissection</kwd><kwd>robot-assisted radical prostatectomy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>локализованный рак предстательной железы</kwd><kwd>ICG-диагностика</kwd><kwd>робот-ассистированная тазовая лимфаденэктомия</kwd><kwd>робот-ассистированная радикальная простатэктомия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Wilt T.J., Brawer M.K., Jones K.M. et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367(3):203–13. DOI: 10.1056/NEJMoa1113162. PMID: 22808955.</mixed-citation><mixed-citation xml:lang="ru">Wilt T.J., Brawer M.K., Jones K.M. et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367(3):203–13. DOI: 10.1056/NEJMoa1113162. PMID: 22808955.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Bill-Axelson A., Holmberg L., Garmo H. et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370(10):932–42. DOI: 10.1056/NEJMoa1311593. PMID: 24597866.</mixed-citation><mixed-citation xml:lang="ru">Bill-Axelson A., Holmberg L., Garmo H. et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370(10):932–42. DOI: 10.1056/NEJMoa1311593. PMID: 24597866.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Yaxley J.W., Coughlin G.D., Chambers S.K. et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet 2016;388(10049):1057–66. DOI: 10.1016/S0140-6736(16)30592-X. PMID: 27474375.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Allan C., Ilic D. Laparoscopic versus robotic-assisted radical prostatectomy for the treatment of localised prostate cancer: a systematic review. Urol Int 2016;96(4):373–8. DOI: 10.1159/000435861. PMID: 26201500.</mixed-citation></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Fossati N., Willemse P.M., Van den Broeck T. et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. Eur Urol 2017;72(1):84–109. DOI: 10.1016/j.eururo.2016.12.003. PMID: 28126351.</mixed-citation><mixed-citation xml:lang="ru">Fossati N., Willemse P.M., Van den Broeck T. et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. Eur Urol 2017;72(1):84–109. DOI: 10.1016/j.eururo.2016.12.003. PMID: 28126351.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><mixed-citation>Harisinghani M.G., Barentsz J., Hahn P.F. et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348(25):2491– 9. DOI: 10.1056/NEJMoa022749. PMID: 12815134.</mixed-citation></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Abdollah F., Gandaglia G., Suardi N. et al. More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer. Eur Urol 2015;67(2):212–9. DOI: 10.1016/j.eururo.2014.05.011. PMID: 24882672.</mixed-citation><mixed-citation xml:lang="ru">Abdollah F., Gandaglia G., Suardi N. et al. More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer. Eur Urol 2015;67(2):212–9. DOI: 10.1016/j.eururo.2014.05.011. PMID: 24882672.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><mixed-citation>Hövels A.M., Heesakkers R.A., Adang E.M. et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a metaanalysis. Clin Radiol 2008;63(4):387–95. DOI: 10.1016/j.crad.2007.05.022. PMID: 18325358.</mixed-citation></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Daneshmand S., Quek M.L., Stein J.P. et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004;172(6 Pt 1):2252–5. PMID: 15538242.</mixed-citation><mixed-citation xml:lang="ru">Daneshmand S., Quek M.L., Stein J.P. et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004;172(6 Pt 1):2252–5. PMID: 15538242.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Sanda G., Chen R., Crispino T. et al. Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline, 2017.</mixed-citation><mixed-citation xml:lang="ru">Sanda G., Chen R., Crispino T. et al. Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline, 2017.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Mottet N., Bellmunt J., Briers E. et al. EAU–ESTRO–SIOG Prostate Cancer Guidelines, 2017.</mixed-citation><mixed-citation xml:lang="ru">Mottet N., Bellmunt J., Briers E. et al. EAU–ESTRO–SIOG Prostate Cancer Guidelines, 2017.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><mixed-citation>Tobis S., Knopf J.K., Silvers C. et al. Robot-assisted and laparoscopic partial nephrectomy with near infrared fluorescence imaging. J Endourol 2012;26(7):797–802. DOI: 10.1089/end.2011.0604. PMID: 22250958.</mixed-citation></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Manny T.B., Patel M., Hemal A.K. Fluorescence-enhanced robotic radical prostatectomy using real-time lymphangiography and tissue marking with percutaneous injection of unconjugated indocyanine green: the initial clinical experience in 50 patients. Eur Urol 2014;65(6):1162–8. DOI: 10.1016/j.eururo.2013.11.017. PMID: 24289911.</mixed-citation><mixed-citation xml:lang="ru">Manny T.B., Patel M., Hemal A.K. Fluorescence-enhanced robotic radical prostatectomy using real-time lymphangiography and tissue marking with percutaneous injection of unconjugated indocyanine green: the initial clinical experience in 50 patients. Eur Urol 2014;65(6):1162–8. DOI: 10.1016/j.eururo.2013.11.017. PMID: 24289911.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><mixed-citation>Steineck G., Helgesen F., Adolfsson J. et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347(11):790–6. DOI: 10.1056/NEJ-Moa021483. PMID: 12226149.</mixed-citation></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">van As N.J., Norman A.R., Thomas K. et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008;54(6):1297–305. DOI: 10.1016/j.eururo.2008.02.039. PMID: 18342430.</mixed-citation><mixed-citation xml:lang="ru">van As N.J., Norman A.R., Thomas K. et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008;54(6):1297–305. DOI: 10.1016/j.eururo.2008.02.039. PMID: 18342430.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Carter H.B., Kettermann A., Warlick C. et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007;178(6):2359–64. DOI: 10.1016/j.juro.2007.08.039. PMID: 17936806.</mixed-citation><mixed-citation xml:lang="ru">Carter H.B., Kettermann A., Warlick C. et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007;178(6):2359–64. DOI: 10.1016/j.juro.2007.08.039. PMID: 17936806.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Seiler R., Studer U.E., Tschan K. et al. Removal of limited nodal disease in patients undergoing radical prostatectomy: long-term results confirm a chance for cure. J Urol 2014;191(5):1280–5. DOI: 10.1016/j.juro.2013.11.029. PMID: 24262495.</mixed-citation><mixed-citation xml:lang="ru">Seiler R., Studer U.E., Tschan K. et al. Removal of limited nodal disease in patients undergoing radical prostatectomy: long-term results confirm a chance for cure. J Urol 2014;191(5):1280–5. DOI: 10.1016/j.juro.2013.11.029. PMID: 24262495.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><mixed-citation>Briganti A., Chun F.K., Salonia A. et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 2006;49(6):1019–26. DOI: 10.1016/j.eururo.2006.01.043. PMID: 16530933.</mixed-citation></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Ramírez-Backhaus M., Mira Moreno A., Gómez Ferrer A. et al. Indocyanine green guided pelvic lymph node dissection: an efficient technique to classify the lymph node status of patients with prostate cancer who underwent radical prostatectomy. J Urol 2016;196(5):1429–35. DOI: 10.1016/j.juro.2016.05.087. PMID: 27235788.</mixed-citation><mixed-citation xml:lang="ru">Ramírez-Backhaus M., Mira Moreno A., Gómez Ferrer A. et al. Indocyanine green guided pelvic lymph node dissection: an efficient technique to classify the lymph node status of patients with prostate cancer who underwent radical prostatectomy. J Urol 2016;196(5):1429–35. DOI: 10.1016/j.juro.2016.05.087. PMID: 27235788.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Yee D.S., Katz D.J., Godoy G. et al. Extended pelvic lymph node dissection in robotic-assisted radical prostatectomy: surgical technique and initial experience. Urology. 2010 May;75(5):1199–204. DOI: 10.1016/j.urology.2009.06.103. PMID: 20163838.</mixed-citation><mixed-citation xml:lang="ru">Yee D.S., Katz D.J., Godoy G. et al. Extended pelvic lymph node dissection in robotic-assisted radical prostatectomy: surgical technique and initial experience. Urology. 2010 May;75(5):1199–204. DOI: 10.1016/j.urology.2009.06.103. PMID: 20163838.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><mixed-citation>Winter A., Vogt C., Weckermann D., Wawroschek F. Complications of pelvic lymphadenectomy in clinically localised prostate cancer: different techniques in comparison and dependency on the number of removed lymph nodes. Aktuelle Urol 2011;42(3):179–83. DOI: 10.1055/s-0031-1271389.</mixed-citation></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">van der Poel H.G., Grivas N. Towards an individualized approach for predicting postprostatectomy urinary incontinence: the role of nerve preservation and urethral stump length. BJU Int 2018;122(3):354–5. DOI: 10.1111/bju.14205. PMID: 30187656.</mixed-citation><mixed-citation xml:lang="ru">van der Poel H.G., Grivas N. Towards an individualized approach for predicting postprostatectomy urinary incontinence: the role of nerve preservation and urethral stump length. BJU Int 2018;122(3):354–5. DOI: 10.1111/bju.14205. PMID: 30187656.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">van der Poel H.G., Buckle T., Brouwer O.R. et al. Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur Urol 2011;60(4):826–33. DOI: 10.1016/j.eururo.2011.03.024. PMID: 21458154.</mixed-citation><mixed-citation xml:lang="ru">van der Poel H.G., Buckle T., Brouwer O.R. et al. Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur Urol 2011;60(4):826–33. DOI: 10.1016/j.eururo.2011.03.024. PMID: 21458154.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Nguyen D.P., Huber P.M., Metzger T.A. et al. A specific mapping study using fluorescence sentinel lymph node detection in patients with intermediate- and high-risk prostate cancer undergoing extended pelvic lymph node dissection. Eur Urol 2016;70(5):734–7. DOI: 10.1016/j.eururo.2016.01.034. PMID: 26856960.</mixed-citation><mixed-citation xml:lang="ru">Nguyen D.P., Huber P.M., Metzger T.A. et al. A specific mapping study using fluorescence sentinel lymph node detection in patients with intermediate- and high-risk prostate cancer undergoing extended pelvic lymph node dissection. Eur Urol 2016;70(5):734–7. DOI: 10.1016/j.eururo.2016.01.034. PMID: 26856960.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><mixed-citation>Chennamsetty A., Zhumkhawala A., Tobis S.B. et al. Lymph node fluorescence during robot-assisted radical prostatectomy with indocyanine green: prospective dosing analysis. Clin Genitourin Cancer 2017;15(4):e529–34. DOI: 10.1016/j.clgc.2016.10.014. PMID: 27939590.</mixed-citation></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">van den Berg N.S., Buckle T., KleinJan G.H. et al. Multispectral fluorescence imaging during robot-assisted laparoscopic sentinel node biopsy: a first step towards a fluorescence-based anatomic roadmap. Eur Urol 2017;72(1):110–7. DOI: 10.1016/j.eururo.2016.06.012. PMID: 27345689.</mixed-citation><mixed-citation xml:lang="ru">van den Berg N.S., Buckle T., KleinJan G.H. et al. Multispectral fluorescence imaging during robot-assisted laparoscopic sentinel node biopsy: a first step towards a fluorescence-based anatomic roadmap. Eur Urol 2017;72(1):110–7. DOI: 10.1016/j.eururo.2016.06.012. PMID: 27345689.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
